Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice

Jun Yang, Jennifer Bratt, Lisa Franzi, Jun Yan Liu, Guodong Zhang, Amir Zeki, Christoph F A Vogel, Keisha Williams, Hua Dong, Yanping Lin, Sung Hee Hwang, Nicholas Kenyon, Bruce D. Hammock

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proin flammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposedmice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.

Original languageEnglish (US)
Pages (from-to)46-55
Number of pages10
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume52
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Epoxide Hydrolases
Ovalbumin
Inflammation
Asthma
Bronchoalveolar Lavage Fluid
Bronchoalveolar Lavage
Chemokines
Acids
Cell Count
Pharmacology
Cytokines
Respiratory system
Lung Compliance
Chemokine CCL5
Th2 Cells
Airway Management
Fluids
Interleukin-5
Eosinophils
Interleukin-4

Keywords

  • Asthma
  • Inflammation
  • Lipid mediators
  • Soluble epoxide hydrolase
  • Type 2 T helper cell cytokines

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice. / Yang, Jun; Bratt, Jennifer; Franzi, Lisa; Liu, Jun Yan; Zhang, Guodong; Zeki, Amir; Vogel, Christoph F A; Williams, Keisha; Dong, Hua; Lin, Yanping; Hwang, Sung Hee; Kenyon, Nicholas; Hammock, Bruce D.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 52, No. 1, 01.01.2015, p. 46-55.

Research output: Contribution to journalArticle

Yang, J, Bratt, J, Franzi, L, Liu, JY, Zhang, G, Zeki, A, Vogel, CFA, Williams, K, Dong, H, Lin, Y, Hwang, SH, Kenyon, N & Hammock, BD 2015, 'Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice', American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 1, pp. 46-55. https://doi.org/10.1165/rcmb.2013-0440OC
Yang, Jun ; Bratt, Jennifer ; Franzi, Lisa ; Liu, Jun Yan ; Zhang, Guodong ; Zeki, Amir ; Vogel, Christoph F A ; Williams, Keisha ; Dong, Hua ; Lin, Yanping ; Hwang, Sung Hee ; Kenyon, Nicholas ; Hammock, Bruce D. / Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice. In: American Journal of Respiratory Cell and Molecular Biology. 2015 ; Vol. 52, No. 1. pp. 46-55.
@article{f4adcb9462b84dc29a44ba200ab451b0,
title = "Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice",
abstract = "Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proin flammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposedmice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.",
keywords = "Asthma, Inflammation, Lipid mediators, Soluble epoxide hydrolase, Type 2 T helper cell cytokines",
author = "Jun Yang and Jennifer Bratt and Lisa Franzi and Liu, {Jun Yan} and Guodong Zhang and Amir Zeki and Vogel, {Christoph F A} and Keisha Williams and Hua Dong and Yanping Lin and Hwang, {Sung Hee} and Nicholas Kenyon and Hammock, {Bruce D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1165/rcmb.2013-0440OC",
language = "English (US)",
volume = "52",
pages = "46--55",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice

AU - Yang, Jun

AU - Bratt, Jennifer

AU - Franzi, Lisa

AU - Liu, Jun Yan

AU - Zhang, Guodong

AU - Zeki, Amir

AU - Vogel, Christoph F A

AU - Williams, Keisha

AU - Dong, Hua

AU - Lin, Yanping

AU - Hwang, Sung Hee

AU - Kenyon, Nicholas

AU - Hammock, Bruce D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proin flammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposedmice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.

AB - Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proin flammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposedmice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.

KW - Asthma

KW - Inflammation

KW - Lipid mediators

KW - Soluble epoxide hydrolase

KW - Type 2 T helper cell cytokines

UR - http://www.scopus.com/inward/record.url?scp=84920266520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920266520&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2013-0440OC

DO - 10.1165/rcmb.2013-0440OC

M3 - Article

C2 - 24922186

AN - SCOPUS:84920266520

VL - 52

SP - 46

EP - 55

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 1

ER -